Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Breeda O’Donoghue told her GP she was having no problems with the medication as the dose was increased slightly over time.

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

An inquest heard Breeda O’Donoghue was “fine” and in “good health” until she took medication in a bid to lose weight ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...